We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Peptide-Enhanced Anticancer Drug Targets Bone Metastasis

Peptide-Enhanced Anticancer Drug Targets Bone Metastasis

Peptide-Enhanced Anticancer Drug Targets Bone Metastasis

Peptide-Enhanced Anticancer Drug Targets Bone Metastasis

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Peptide-Enhanced Anticancer Drug Targets Bone Metastasis"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone.

A study by scientists at Rice University and Baylor College of Medicine demonstrated the effective treatment of such cancers in rodent models, bringing hope for new therapies to treat bone metastases.

The open-access study, to appear on the cover of the American Chemical Society journal ACS Central Science, advances techniques pioneered by Rice chemist Han Xiao and his co-author at Baylor, biologist Xiang Zhang.

They discovered through extensive testing that engineering “bone-homing” peptides and attaching them to a common breast cancer drug, the antibody trastuzumab, effectively targets and attacks bone tumors.

The researchers reported their surprise that injecting more of the drug compound doesn’t make it better. The drug contains an engineered peptide that finds and binds to bone, but worked best when a moderate amount was delivered.

“The negative charge of the peptide has an affinity for the positively charged bone cancer niche,” said Xiao, whose lab created a library of modified antibodies for testing. “We found the therapeutic efficacy is best with the antibody that has mediocre affinity. That’s a really big discovery.”

As many as 40% of breast cancer survivors eventually experience metastases to distant organs, most often to the bone. Xiao noted bone tumors are notoriously difficult to treat, given the hard nature of the material and its limited vascular network. Delivering a low amount of a drug, he said, can also help tumors develop resistance.

The study showed that peptide-enhanced antibodies also prevented secondary metastases from bone to other organs.

The researchers hope to find collaborators to move the strategy toward human trials. 

Reference: Tian Z, Yu C, Zhang W, et al. Bone-specific enhancement of antibody therapy for breast cancer metastasis to bone. ACS Cent Sci. 2022. doi: 10.1021/acscentsci.1c01024

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.